

Attorney Docket No. 43939-1 (formerly 21059/0206964-USO)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Bakulesh M. Khamar et al.

Examiner: Rodney P. Swartz

Application Serial No.: 10/583,731

Group Art Unit: 1645

Filing Date: February 19, 2008

Priority Application: PCT/IB06/00978 filed April 21, 2006

Indian application no. 505/MUM/2005 filed April 25, 2005

For: VACCINE ADJUVANTS

**CERTIFICATION UNDER 37 C.F.R. 1.373(B) SUPPLEMENTING A POWER OF
ATTORNEY FILED IN THE ABOVE APPLICATION**

The undersigned, Bakulesh M. Khamar ^{MS} (Ph.D.), states:

1. I am the Executive Director of Cadila Pharmaceuticals Limited ("Cadila") of India, assignee of the above cited application, and duly empowered to act for it in patent application matters. I am also a named co-applicant/co-inventor of the above cited application.

2. The U.S. patent application is a 35 U.S.C. § 371 national phase entry of the PCT application cited above and indicating Applicants as Cadila for all countries (except the United States) and the inventions for the U.S. a pattern of many U.S. applications by Cadila. That pattern also includes recording assignments of individual inventors and the pattern was followed in this case with an assignment recorded at Reel 020526 Frame 0562, recorded by the U.S. Patent & Trademark Office Assignment Branch on February 19, 2008.

Given under pains and penalties of perjury of U.S. law.

Dated: September th 6, 2010

^{1. Khamar B.M.}

Bakulesh M. Khamar
Executive Director
Cadila Pharmaceuticals Limited

Enclosure: Power of Attorney

01499270.DOC